AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
COVID-19 Clearinghouse is the go-to platform for directly accessing the latest information and research about the coronavirus and COVID-19.
ESCHBORN, Germany, Boston, M.A. and Durham, N.C., May 11, 2021 – Innoplexus, a global leader in AI-based drug discovery and development, and Parexel, a leading global clinical research organization, have expanded the features and functionality of their COVID-19 Clearinghouse platform to enhance the public’s access to the latest COVID-19 publications, datasets, clinical trial information and current news in a single, online repository.
Launched in September 2020, the platform’s new upgrades provide more advanced search capabilities that better pinpoint relevant information; a wider range of filters and feedback features to improve the user experience; mobile and tablet-friendly layouts for easy and intuitive browsing; and compatibility improvements for the four biggest browsers. The goal of the COVID-19 Clearinghouse is to help researchers, sponsors and patients overcome barriers to accessing accurate data about the pandemic.
“The pandemic has unfolded with such speed and virulence that the sheer volume of scientific and clinical information we’ve amassed about the virus and the disease requires a comprehensive, ordered and searchable repository for finding specific information quickly and efficiently,” said Michelle Hoiseth, Chief Data Officer for Parexel. “Leveraging Innoplexus’ technology, our Scientific Data organization has automated the collection and organization of COVID data points pulled from thousands of structured and unstructured datasets, publications, clinical trials and news sources that are deemed credible and reliable from a scientific perspective.”
Provided as a service to the public, physicians and the healthcare industry, the COVID-19 Clearinghouse incorporates information from 22,856 datasets, 186,236 publications, 8,358 clinical trials and 847,667 timely news articles from across 100+ different geographies. This corpus is updated in real-time to capture the latest research activity around the globe.
While the clearinghouse is accessible to anyone seeking information related to COVID-19 — from patients and physicians to regulators and sponsors — researchers will benefit from a consolidated repository of information as they seek to leverage verified data points to develop new therapies and approaches to respond to the pandemic.
Initial use of the platform by researchers and the public has provided important insights leading to upgrades and enhancements that will further enhance the user experience.
Innoplexus is a leading global AI-based platform for drug discovery and development with over 250 employees and 100+ patent applications including 32 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus’ solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unprecedented speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.
Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life science and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. Parexel was named “Best Contract Research Organization” in December 2020 by an independent panel for Informa Pharma Intelligence. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.